Search
for
Sort by
Research 121–150 of 523
- Kaempferol enhances hair growth by regulating JAK3/STAT6 and TGF-β/Smad signaling in human dermal papilla cells and a C57BL/6 mousemodel
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
- Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Janus kinase inhibitors for alopecia areata: A narrative review
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Use of Jak Inhibitors in the Treatment of Alopecia Areata
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
- 1325 Age-dependent loss of the stemness and antimicrobial defense function of dermal fibroblasts is mediated by TGFbeta
- Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia?
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Ritlecitinib: First Approval
- Tofacitinib for the treatment of lichen planopilaris: A case series
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm